Celltrion's Remsima Gains Significant Market Share in Europe

Celltrion, a South Korean biopharmaceutical company, has announced that its autoimmune biosimilar infliximab products, Remsima and Remsima SC, have achieved a combined market share of around 74% in the EU5 countries (UK, Germany, France, Spain, and Italy) as of Q4 2023. This represents a substantial increase from the 60% market share reported in the previous year.

Remsima, which references Janssen Biotech's Remicade, has proven effective in treating various diseases, including rheumatoid arthritis and Crohn's disease. The introduction of Remsima SC, a subcutaneous formulation, has further driven the growth of Celltrion's market share.

The convenience of self-administration and the ability for patients to switch between the intravenous and subcutaneous formulations have contributed to the success of both products.

Celltrion attributes the market share gains to several factors, including its sales capabilities, increased trust in the company's products, and successful performance in key tenders. The continued publication of study results demonstrating the efficacy and safety of Remsima SC, along with the accumulation of real-world prescribing data, is expected to further drive share growth for the Remsima product line.

Why this matters: Celltrion's increasing market share in Europe for its biosimilar products highlights the growing acceptance and adoption of biosimilars in the healthcare industry. The success of Remsima and Remsima SC could lead to increased competition, potentially driving down costs and improving patient access to these treatments.

In addition to the success of Remsima, Celltrion's other biosimilar products, such as Vegzelma (bevacizumab), Yuflyma (adalimumab), Herzuma (trastuzumab), and Truxima (rituximab), are also seeing increased market share in Europe. The company attributes this growth to its customized sales strategy and bidding plan that takes into account country-specific healthcare market characteristics.

Looking ahead, Celltrion is optimistic about the potential success of Zymfentra (Remsima SC) in the U.S. market and plans to build upon its European results and pipeline of upcoming launches. "The combined market share of Remsima and Remsima SC hit 74% in Britain, Germany, France, Spain and Italy in the fourth quarter of last year, up 12 percentage points from the corresponding tally for 2020 when Remsima SC was released," stated a company representative.

Key Takeaways

• Celltrion's biosimilar infliximab products Remsima and Remsima SC have 74% EU5 market share.
• Remsima SC, a subcutaneous formulation, has driven growth of Celltrion's market share.
• Celltrion attributes gains to sales capabilities, trust, and successful tenders.
• Celltrion's other biosimilars also see increased EU market share due to customized strategies.
• Celltrion is optimistic about Remsima SC's potential success in the U.S. market.